Investors seeking growth at a reasonable cost should explore NYSE:DOCS.

Consider DOXIMITY INC-CLASS A (NYSE:DOCS) as an affordable growth stock, identified by our stock screening tool. NYSE:DOCS is showcasing impressive growth figures and is well-positioned in terms of profitability, solvency, and liquidity. Moreover, it seems to be priced reasonably. Let's dive deeper into the analysis.

Understanding NYSE:DOCS's Growth

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NYSE:DOCS has achieved a 8 out of 10:

• DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.94%, which is quite impressive.
• The Earnings Per Share has been growing by 81.49% on average over the past years. This is a very strong growth
• Looking at the last year, DOCS shows a quite strong growth in Revenue. The Revenue has grown by 15.27% in the last year.
• Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 40.87% on average per year.
• The Earnings Per Share is expected to grow by 13.57% on average over the next years. This is quite good.
• DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.03% yearly.

How do we evaluate the Valuation for NYSE:DOCS?

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NYSE:DOCS has achieved a 5 out of 10:

• Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than the industry average as 75.68% of the companies are valued more expensively.
• Based on the Price/Forward Earnings ratio, DOCS is valued a bit cheaper than 78.38% of the companies in the same industry.
• DOCS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.87.
• Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 67.57% of the companies listed in the same industry.
• Compared to the rest of the industry, the Price/Free Cash Flow ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 64.86% of the companies listed in the same industry.
• DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
• DOCS's earnings are expected to grow with 14.92% in the coming years. This may justify a more expensive valuation.

Assessing Health for NYSE:DOCS

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:DOCS has received a 9 out of 10:

• DOCS has an Altman-Z score of 44.14. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
• The Altman-Z score of DOCS (44.14) is better than 100.00% of its industry peers.
• DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
• A Current Ratio of 7.24 indicates that DOCS has no problem at all paying its short term obligations.
• With an excellent Current ratio value of 7.24, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
• DOCS has a Quick Ratio of 7.24. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
• With an excellent Quick ratio value of 7.24, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

Profitability Examination for NYSE:DOCS

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:DOCS, the assigned 9 is a significant indicator of profitability:

• DOCS has a Return On Assets of 15.57%. This is amongst the best in the industry. DOCS outperforms 97.30% of its industry peers.
• Looking at the Return On Equity, with a value of 18.11%, DOCS belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
• DOCS's Return On Invested Capital of 16.83% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
• DOCS had an Average Return On Invested Capital over the past 3 years of 12.02%. This is significantly above the industry average of 6.36%.
• The 3 year average ROIC (12.02%) for DOCS is below the current ROIC(16.83%), indicating increased profibility in the last year.
• The Profit Margin of DOCS (33.69%) is better than 97.30% of its industry peers.
• In the last couple of years the Profit Margin of DOCS has grown nicely.
• DOCS has a better Operating Margin (39.06%) than 100.00% of its industry peers.
• DOCS's Operating Margin has improved in the last couple of years.
• DOCS has a better Gross Margin (89.94%) than 97.30% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

For an up to date full fundamental analysis you can check the fundamental report of DOCS

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.